CD Diagnostics’ focus is to provide physicians with analytical tools that enable them to make informed decisions that will improve patient outcomes. We will bring these analytical tools to market through corporate partnerships.

AWARDS FOR JOINT FLUID RESEARCH

- Mark Coventry Award
- OREF Research Award
- Smith & Nephew National Research Award
- National Arthroscopy Association Award
- Enterprise Award: Emerging Life Science Company
- Discovery Channel feature on “Health Heroes”
- Jeannette Wilkins Award for Best Basic Science Paper
- Best Product Innovation of Zimmer in 2014

OVERVIEW

CD Diagnostics is a fully integrated diagnostics company focused on developing immunoassays that improve patient outcomes. The company holds patents on biomarker diagnostics and currently offers seven unique tests. Its first product, Synovasure® PJI, is a joint infection test available as a laboratory developed test in the US, and CE marked in both ELISA plate and lateral flow formats in Europe. CD Diagnostics also provides clinical testing services through its subsidiary CLIA laboratory, Citrano Medical Laboratories. Citrano Medical Laboratories is a key component in the company’s commercialization strategy, as it allows CD Diagnostics to rapidly commercialize products with well-established automated systems for result reporting and billing. Research on the Synovasure infection diagnostic test has led to breakthroughs in the areas of sepsis and bacterial meningitis. These diseases are similar infections, but found in different matrices; synovial fluid, blood, and cerebrospinal fluid respectively. CD Diagnostics’ product developments include direct bacterial antigen detection as well as biomarker detection.

FEATURED PRODUCT

Synovasure® PJI

Synovasure® PJI is a synovial fluid test that capitalizes on the alpha defensin biomarker. The test has revolutionized the orthopaedic market with its ease of use, rapid time to result, and superior performance compared to previous diagnostic methods. Synovasure is currently used by over 2,000 surgeons. Independent evaluations have been conducted by leading institutions which have published their findings in prominent orthopaedic journals.

For a complete list of references and peer reviewed articles on alpha defensin, please visit our website or use the link below.
CORPORATE HISTORY

CD Diagnostics incorporated in December 2011. Six months later, in June 2012, the company signed its first corporate partnership with Zimmer, a leading orthopaedic company. The partnership provided funding for the development of Synovasure®, CD Diagnostics’ proprietary joint infection test. Soon after, CD Diagnostics purchased a controlling interest in Citrano Medical Laboratories, a CLIA certified laboratory in Baltimore, Maryland. Synovasure® PJ1 was released as an LTD through a pilot program in early 2013, and became commercially available in October 2013. In May 2014, CD Diagnostics relocated its corporate headquarters to a state-of-the-art 20,000 SF facility in Claymont, Delaware. In this new facility, CD Diagnostics’ manufacturing capacity has grown to 50 million tests/year. The laboratory version of Synovasure was CE marked for sale in Europe in June 2014. The on-site, or point of care, device followed in November 2014. Based on the commercial success of Synovasure®, the original development agreement with Zimmer has been expanded to include the development of four additional diagnostic tests. CD Diagnostics has a track record of innovation (Mark Coventry Award, Enterprise Award, Zimmer 2014 Innovative Product of the Year, Delaware BioScience Association 2015 Innovation Award), developing innovative tests that provide more accurate results in a timely fashion.

FINANCIALS

CD Diagnostics raised $5.2 million in a Preferred A round of financing which was completed in September 2012. The lead participants in the Preferred A were BioStar Ventures, Vital Financial, and Zimmer. Current 2015 revenue through June is $5.6 million, assets are $7.8 million. Year to date, we realized a net income of $762,000.

### Financials

<table>
<thead>
<tr>
<th>(in thousands)</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015 Projected</th>
<th>2015 (June)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$0</td>
<td>$3,782</td>
<td>$5,896</td>
<td>$7,475</td>
<td>$12,878</td>
<td>$5,649</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>$0</td>
<td>$2,953</td>
<td>$3,440</td>
<td>$4,673</td>
<td>$9,549</td>
<td>$4,137</td>
</tr>
<tr>
<td>R&amp;D Expense</td>
<td>$445</td>
<td>$2,740</td>
<td>$3,850</td>
<td>$4,140</td>
<td>$5,200</td>
<td>$2,009</td>
</tr>
<tr>
<td>Total Expense</td>
<td>$743</td>
<td>$3,921</td>
<td>$5,932</td>
<td>$6,376</td>
<td>$9,251</td>
<td>$3,241</td>
</tr>
<tr>
<td>Net Income (Loss)</td>
<td>$(743)</td>
<td>$(968)</td>
<td>$(2,402)</td>
<td>$(1,931)</td>
<td>$(35)</td>
<td>$(762)</td>
</tr>
</tbody>
</table>

| Assets              | $991   | $9,488  | $7,173  | $6,882  | $6,634         | $7,783      |
| Liabilities         | $1,666 | $1,415  | $1,113  | $2,245  | $2,052         | $2,937      |
| Shareholder’s Equity| $(675) | $8,073  | $6,060  | $4,637  | $4,581         | $4,846      |
| Net Cash Used for Operations | $(528) | $(1,446)| $(515)  | $(1,022)| $(124)         | $983        |

TARGET MARKETS

**Orthopaedics**

Joint disease encompasses over 150 conditions and syndromes, which are usually progressive and associated with pain. Worldwide, 1.7 billion people suffer from joint pain and disease. A recent national survey reported that over 84 million office visits were made annually in the US due to joint pain and disease. In each of these cases, infection must be ruled out as the source of pain and inflammation. CD Diagnostics is developing additional synovial fluid diagnostic tests aimed at various joint diseases, including osteoarthritis, which affects over 27 million Americans.

**Bacterial Meningitis & Sepsis**

Bacterial meningitis is typically severe and can lead to brain damage, hearing loss, learning disabilities, and death. Diagnosis currently involves a spinal puncture and culture of cerebrospinal fluid. Over 400,000 spinal punctures are performed every year in the US. However, cultures lack the sensitivity and speed needed to accurately and quickly diagnose most infectious diseases. In third world countries, the lack of access to healthcare and simple diagnostic tests leads to higher mortality rates, especially among children. While there has been some advancement in diagnosing sepsis, blood cultures continue to be the gold standard. There are 81.5 million blood cultures performed in the US. There is a clear need for simple diagnostic tests for these indications.